Enzalutamide (MDV3100)

For research use only. Not for use in humans.

製品コードS1250

Enzalutamide (MDV3100)化学構造

CAS No. 915087-33-1

Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.

サイズ 価格(税別)  
JPY 26900
JPY 46800
JPY 129800
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(343)

製品安全説明書

Androgen Receptor阻害剤の選択性比較

生物活性

製品説明 Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.
ターゲット
Androgen Receptor [1]
(LNCaP cells)
36 nM
体外試験

Enzalutamide has greater affinity to AR than Bicalutamide does in a competition assay with 16β-[18F]fluoro-5α-DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide could inhibit the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys). [1] Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LNCAP NYPhNVVYS3m2b4TvfIlkKEG|c3H5 NE\jcI84KGSjeYO= M1HEZVk2LSCHdF;I MWnJR|UxRTVwMUKg{txO MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUO1OlcoRjJ|N{GzOVY4RC:jPh?=
human LNCAP MVfGeY5kfGmxbjDBd5NigQ>? MkDrNUDPxE1? NETSXFRFVVOR Ml3WTY5pcWKrdIOgdJJwe3SjdHWgd5Bm[2moaXOgZY51cWenbjDz[YNz\XSrb36gbY4hcHWvYX6gUG5ESVBiY3XscJMh\XiycnXzd4lv\yCjbnTyc4dmdiC{ZXPldJRweiCjdDCxNFAuOTByMH7N MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJzOEexO{c,OjB{MUi3NVc9N2F-
VCaP NFu4OIVHfW6ldHnvckBCe3OjeR?= MXexNEDPxE1? MnHqNlQhcA>? MX3EUXNQ NFzUUW9UfXCycnXzd4V{KGyrZ3Hu[E1u\WSrYYTl[EBCWi2ITDDzbYdv[Wyrbne= NFizN3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkexNFQ{Pid-MkK3NVA1OzZ:L3G+
BCK4 NX\pd25nTnWwY4Tpc44hSXO|YYm= MVyxNEDPxE1? MorjO{Bl[Xm| M1PWdWROW09? NU\OeVY{UW6qaXLpeJMh\XO2cnHkbY9tNW2nZHnheIVlKHC{b3zp[oVz[XSrb36= MnHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NUGxNFkoRjJ2NEWxNVA6RC:jPh?=
MCF7s NIXufoZHfW6ldHnvckBCe3OjeR?= MW[xNEDPxE1? M4PZVFYh\GG7cx?= MmrhSG1UVw>? NVzSWFVDUW6qaXLpeJMh\XO2cnHkbY9tNW2nZHnheIVlKHC{b3zp[oVz[XSrb36= NGXKbW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES1NVExQSd-MkS0OVEyODl:L3G+
PC-3 M1nZOGZ2dmO2aX;uJGF{e2G7 MVqxNEDPxE1? M2P2OFczKGh? MYnEUXNQ MnjVSI9meyCwb4SgbY5pcWKrdDDj[YxtKHC{b3zp[oVz[XSrb36= NFrsXWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO0OFg3PCd-MkWzOFQ5PjR:L3G+
CWR22Rv1 MWHGeY5kfGmxbjDBd5NigQ>? NIrhUnEyPSEQvF2= NY\CPZRROjRiaB?= MYTEUXNQ NFSzZoxFd2W|IH7veEBi\m[nY4SgeIhmKG[3bHygcIVv\3SqIFHSJIV5eHKnc4Ppc44> NF\OeHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exN|U3Pyd-MkO3NVM2Pjd:L3G+
LNCAP/AR MUDBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NFvXUHFKSzVyIE2gNE4xOjFizszN NYLpcopHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NVc2PDRpPkK3O|E4PTR2PD;hQi=>
MDA-MB-453 NWL2eGpQSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> M{\OT2VEPTBiPTCwMlA1QSEQvF2= NF[zcmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exN|U3Pyd-MkO3NVM2Pjd:L3G+
LNCAP NWDvWJVSSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> M4npZlczKGh? M2fmU2lEPTBiPTCwMlA2KM7:TR?= M{DJO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUmzNlE2Lz5|MEG5N|IyPTxxYU6=
LNCAP NE\UVVRCdnSjZ3;ubZN1KGGldHn2bZR6KGG|c3H5 MWW3NkBp Mof3TWM2OCB;IECuNFkh|ryP NW\nUpJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxPVMzOTVpPkOwNVk{OjF3PD;hQi=>
LNCAP MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rTSmdKPTBiPTCwMlEzKM7:TR?= MmnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyMUGyNVkoRjJ6MEGxNlE6RC:jPh?=
LNCAP NWPmSpNwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NEex[4c{KGSjeYO= MlGzTWM2OCB;IECuNVI4OSEQvF2= NWHucm1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFY{OTNpPkK2NFQ3OzF|PD;hQi=>
LNCAP NHf1SnhCdnSjZ3;ubZN1KGGldHn2bZR6KGG|c3H5 NGHZcnY3KGSjeYO= MlT4S2k2OCB;IECuNlkh|ryP MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDBzMUKxPUc,OjhyMUGyNVk9N2F-
UAS-bla GripTite 293 M{XsS2FvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= NHz5TXIyPiC2bzCyOEBp M4jIXWlEPTBiPTCwMlM3OSEQvF2= M2TXcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{CxN|Y5Lz5{N{OwNVM3QDxxYU6=
mammalian expression system MXnBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 M1zOO|IzKHSxIEK0JIg> NXfOUFAxTUN3MDC9JFAvPDJizszN NEHqXHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO4OVUxOyd-MkizPFU2ODN:L3G+
VCaP NULOeVhKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVyxOFQhcA>? MXzHTVUxKD1iMD62NUDPxE1? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{MUW4Okc,OjVzMkG1PFY9N2F-
LNCaP NXnJSItPSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> M2PR[VIhcA>? MmT3SWM2OCB;IECuPVE2KM7:TR?= Mn\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUO1OlcoRjJ|N{GzOVY4RC:jPh?=
COS7 MV7BcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 MkTWNlQhcA>? MVvJR|UxKD1iMT6yOkDPxE1? NEDEZXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGxO|g6Pyd-MkmxNVc5QTd:L3G+
AR LBD mutant MUPBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NGTVV2Q1KGh? MoG4TWM2OCB;IEGuN|Uh|ryP MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW4PUc,Ojd6MUC1PFk9N2F-
LNCAP NED2W3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4LKN2dKPTBiPTCyMlg5KM7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ|NEGzNEc,OjV4M{SxN|A9N2F-
CWR22Rv1 MnKwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXf3[ZpnT0l3MDC9JFMvOzRizszN M4Hr[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO0NVMxLz5{NU[zOFE{ODxxYU6=
LNCAP M2DJXWN6fG:2b4jpZ4l1gSCjc4PhfS=> M1TlNlch\GG7cx?= MY\HTVUxKD1iNT6xNkDPxE1? NEHySoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exN|U3Pyd-MkO3NVM2Pjd:L3G+
PC3 M13oZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mkm0S2k2OCB;IEmuNVUh|ryP M2LkfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO0NVMxLz5{NU[zOFE{ODxxYU6=
CWR22Rv1 M1XlTWNmdGxic4Xyeol3[WxiYYPzZZk> NWXyPIpoOTR2IHi= MmHzTWM2OCB;IEmuO{DPxE1? M1PCNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKxOVg3Lz5{NUGyNVU5PjxxYU6=
LNCAP MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NVzyUIxKQTZiaB?= M4O3VWlEPTBiPTCxNU41PyEQvF2= NGfvTYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{OwNVM3QCd-MkezNFE{Pjh:L3G+
LNCaP-hr MkSwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MXqzJIRigXN? MYLJR|UxKD1iMUKuOUDPxE1? MlLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PFkoRjJ5OEGwOVg6RC:jPh?=
LNCAP MlvCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NWXNUY5oOyCmYYnz MnjETWM2OCB;IEGyMlUh|ryP Moj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMUe4PVcoRjJ7MUG3PFk4RC:jPh?=
LNCaP MWfBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 M2LyRVE1PCCq M3m4UGdKPTBiPTCxPE45QCEQvF2= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ5Mki5OEc,Ojh{N{K4PVQ9N2F-
LNCaP-AR MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4rRS|E1PCCq Mo\KS2k2OCB;IEG4Mlkh|ryP NUDDOJlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlE2QDZpPkK1NVIyPTh4PD;hQi=>
C4-2B M3flZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NWXUc2w3OTJiaB?= M132OmlEPTBiPTCyNE44PyEQvF2= NEL3SJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
A31 MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFfpZWc4OiCq MYjHTVUxKD1iMkeuOUDPxE1? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDBzMUKxPUc,OjhyMUGyNVk9N2F-
22Rv1 M1vSWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MnryPVYhcA>? MUTJR|UxKD1iM{GuO|Yh|ryP MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzNyMUO2PEc,Ojd|MEGzOlg9N2F-
22Rv1 MkHWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NXXG[GZ5QTZiaB?= NVjJbnh6UUN3MDC9JFMyNjd4IN88US=> Mmj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NkW4OlIoRjJ4OU[1PFYzRC:jPh?=
DU145 NYPEeJZ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= Ml7SPVYhcA>? MlXPTWM2OCB;IEOyMlI4KM7:TR?= NVvDO|RwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezNFE{PjhpPkK3N|AyOzZ6PD;hQi=>
LNCAP NHTaZ5dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MWW3NkBp M4\aOGlEPTBiPTCzN{45PCEQvF2= M3\jbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NES4NVM6Lz5{OUS0PFE{QTxxYU6=
CW22Rv1 M{\tSGFvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= NInjfXg4OiCq M3LXS2lEPTBiPTCzOU44PSEQvF2= NX7NOVE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyO|I5QTRpPkK4NlczQDl2PD;hQi=>
22Rv1 NYnSXFM4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MUK3NkBp NGfP[5dKSzVyIE2gN|YvPjZizszN MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR2OEGzPUc,Ojl2NEixN|k9N2F-
22Rv1 MnHORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MXOxNkBp MYjJR|UxKD1iM{[uOlYh|ryP NH3t[|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
LNCAP NX7NXG9NSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NGq5b5IyOiCq MoPjTWM2OCB;IESyMlM4KM7:TR?= NIP1O5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
DU145 M1HDbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M13w[lMh\GG7cx?= M{WycWlEPTBiPTC0Ok4yKM7:TR?= M2PRdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEGwOVg6Lz5{N{ixNFU5QTxxYU6=
DU145 MknERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MkK3N{Bl[Xm| NVruVIw{UUN3MDC9JFQ3NjFizszN NVHidWtyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNVc5QTdpPkK5NVE4QDl5PD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
AR / ERG / NOTCH1 / PSA / Cleaved PARP1 / Cleaved caspase 7; 

PubMed: 28607007     


Treatment of VCaP cells with NOTCH inhibitor, GSI-1, in combination with Enzalutamide (Enz) augmentes its effects on the inhibition of AR, ERG, PSA, NOTCH1 and NOTCH2 expression and induces cleavage of PARP1 and Caspase 7

AR-FL / AR-v7 / pAR(S213) / pAkt(S473) / pMdm2(S166); 

PubMed: 26378044     


LNCaP95 (LN95) cells were maintained in medium containing 5% CSS and then treated with 5μM of enzalutamide (ENZ) for 0-24 hours. Whole cell lyses were extracted. AR-FL, AR-v7, phosphor-AR(ser213), phosphorAkt(ser473), total Akt, total PP-1, phosphor-Mdm2(ser166), total Mdm2 and β-actin were measured by immunoblotting.

CXCR7; 

PubMed: 29277895     


Western blotting is used to analyze CXCR7 protein levels in VCaP and C4-2B cells.

28607007 26378044 29277895
Growth inhibition assay
Cell proliferation; 

PubMed: 28115200     


Proliferation of the LNCaP prostate cancer cell line, the Ramos Burkitt's cell line, and the Granta, Jeko-1, Rec-1 and Maver-1 MCL cell lines plated in charcoal stripped serum for 96 hours in the absence or presence of enzalutamide (10uM). Data are representative of 3 independent experiments.

28115200
Immunofluorescence
AR; 

PubMed: 27588408     


Representative immunofluorescent images show the expression and subcellular localization of AR in 22Rv1 cells overexpressing PIP5K1α that were treated with vehicle control, enzalutamide, ISA-2011B and combination of enzalutamide and ISA-2011B.

pAKT(S473); 

PubMed: 27588408     


Representative immunofluorescent images of subcellular localization of pAKT S473 expression in PC3 cells expressing AR-V7 that were treated with vehicle control (Ctrl), enzalutamide, ISA-2011B and combination of enzalutamide and ISA-2011B (ENZ+ISA2011B). The cancer cells are indicated by the arrows.

CXCR7; 

PubMed: 29277895     


Immunofluorescence staining is used to analyze CXCR7 protein levels in prostate cancer cells.

27588408 29277895
ELISA
osteoprotegerin; 

PubMed: 27015557     


MDA-MB-231 cells were treated with 10 μM enzalutamide or vehicle for 48 hours. Levels of OPG (osteoprotegerin) in the supernatant of MDA-MB-231 cells as determined by ELISA. Data are representative of 2 independent experiments.

27015557
体内試験 Enzalutamide induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[3]
- 合併

AR reporter assay:

Enzalutamide is evaluated by an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells are engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells are also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer. The antagonistic activity of Enzalutamide is tested in the presence of 100 pM of R1881. Engineered LNCaP cells are maintained in Iscove's medium containing 10% fetal bovine serum (FBS). Two days prior to Enzalutamide treatment, the cells are grown in Iscove's medium containing 10% charcoal-stripped FBS (CS-FBS) to deprive of androgens. The cells are split and grown in Iscove's medium containing 10% CS-FBS with 100 pM of R1881 and increasing concentrations of Enzalutamide. After two days of incubation, reporter activities are assayed.
細胞試験: [1]
- 合併
  • 細胞株: LNCaP or LNCaP/AR cells
  • 濃度: 0-10 μM
  • 反応時間: 1-4 days
  • 実験の流れ: Enzalutamide is diluted in DMSO. LNCaP or LNCaP/AR cells (104 cells/well) are androgen-starved by growth in media containing 5-10% charcoal-stripped serum for 3-5 days. Then the cells are challenged with various concentrations of Enzalutamide in media containing 5-10% charcoal-stripped serum.
    (参考用のみ)
動物試験:[1]
- 合併
  • 動物モデル: Castration-resistant LNCaP/HR xenografts in male SCID mice
  • 投薬量: 10 mg/kg
  • 投与方法: Administered via gavage daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 92 mg/mL (198.08 mM) warming
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 464.44
化学式

C21H16F4N4O2S

CAS No. 915087-33-1
Storage powder
in solvent
別名 N/A
Smiles CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04655365 Not yet recruiting Drug: Enzalutamide capsule Prostate Cancer CHU de Quebec-Universite Laval|Astellas Pharma Europe Ltd. January 4 2021 Phase 2
NCT04335682 Not yet recruiting Drug: Darolutamide|Drug: Enzalutamide Metastatic Prostate Cancer|Prostate Cancer Metastatic|Prostate Cancer|Castrate Resistant Prostate Cancer Alliance Foundation Trials LLC.|Bayer September 2020 Phase 2
NCT04456049 Not yet recruiting Drug: Enzalutamide COVID-19 Infection Ricardo Pereira Mestre|Oncology Institute of Southern Switzerland|Institute of Oncology Research|Institute for Research in Biomedicine|Ente Ospedaliero Cantonale Bellinzona July 2020 Phase 2
NCT04443062 Recruiting Drug: 177Lu-PSMA-I&T Prostate Cancer Radboud University|Prostaatkankerstichting July 20 2020 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to inquire about the usage or solubility of S1250, Enzalutamide.

  • 回答:

    For in vivo experiment, S1250 can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 5mg/ml as a suspension for oral gavage. And it can be dissolved in 15% DMSO+85% PEG 300 at 10mg/ml as a clear solution. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG.

Androgen Receptorシグナル伝達経路

Androgen Receptor Inhibitors with Unique Features

相関Androgen Receptor製品

Tags: Enzalutamide (MDV3100)を買う | Enzalutamide (MDV3100) ic50 | Enzalutamide (MDV3100)供給者 | Enzalutamide (MDV3100)を購入する | Enzalutamide (MDV3100)費用 | Enzalutamide (MDV3100)生産者 | オーダーEnzalutamide (MDV3100) | Enzalutamide (MDV3100)化学構造 | Enzalutamide (MDV3100)分子量 | Enzalutamide (MDV3100)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID